Comparative study of serum/plasma glycation and lipid peroxidation of young patients with type 1 diabetes mellitus in relation to glycemic compensation and the occurrence of diabetic complications

Bratislava Medical Journal

Volumn 111, Issue 11, 2010, Pages 578-585

  Kostolanska, J ^a   Jakus, V ^b   Barak, L ^a   Stanikova, A ^a   Waczulikova, I ^c  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^b Bratislava   (Slovakia)

^c Faculty of Natural Sciences   (Slovakia)

Author keywords

Diabetic complications; Glycemic control; HbA1c; Lipoperoxides; s AGEs

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLYCOSYLATED HEMOGLOBIN;

ADOLESCENT; ARTICLE; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION;

ADOLESCENT; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPID PEROXIDATION;

EID: 78649997645     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kvapil M. Diabetes mellitus. Praha; Triton, 2007: 2-190.
2. Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004; 346 (2): 161-170.
3. Gillery P. Oxidative stress and protein glycation in diabetes mellitus. Ann Biol Clin 2006; 64 (4): 309-314.
4. lc not an accurate enough predictor of long term progression and glycaemic control in diabetes? Clin Biochem Rev 2005; 26 (4): 123-134.
5. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 46 (Suppl 2): S19-S25.
6. Jawień J. New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn 2008; 118 (3): 127-131.
7. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem 1997; 272: 22975-22978.
8. Ross R. Atherosclerosis - An Inflammatory Disease. N Engl J Med 1999; 340: 115-126.
9. Galler A, Müller G, Schintzel R, Kratzsch J, Kiess W, Münch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and Nε-(Carboxymethyl)Lysine ELISA. Diabet Care 2003; 26 (9): 2609-2615.
10. Guo X. Pay attention to individualized intensive glycemic control and reducing multiple risk factors of diabetes. Chin Med J (Engl.) 2008; 121 (8): 675-676.
11. Pendergrass M. Does intensive glycemic control improve cardiovascular outcomes? Nat Clin Pract Endocrinol Metab 2008; 4 (10): 529.
12. National Diabetes Data Group. Classification of Diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28 (12): 1039-1057.
13. el-Saadani M, Esterbauer H, el-Sayed M, Goher M, Nassar AY, Jürgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989; 30 (4): 627-630.
14. Bogalho P. Lipid disorders in children with insulin-dependent diabetes mellitus. Acta Med Port 1998; 11 (7): 683-690.
15. Merzouk S, Hichamia A, Sari A, Madani S, Merzouk H, Yahia Berro-uiguet A et al. Impaired oxidant/antioxidant status and LDL-fatty acid composition are associated with increased susceptibility to peroxidation of LDL in diabetic patients. Gen Physiol Biophys 2004; 23 (4): 387-399.
16. Imani SF, Hashemipour M, Kelishadi R. Lipid profile in children with type 1 diabetes compared to controls. Arya J 2006; 2 (1): 36-38.
17. Jakuš V. The role of nonenzymatic glycation and glycoxidation in the development of diabetic vascular complications. Čs Fyziol (Czech) 2003; 52 (2): 51-65.
18. Jakuš V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004; 53 (2): 131-142.
19. Thornalley PJ. The glyoxylase system, new developments towards functional characterization of a metabolic pathways fundamental to biological life. Biochem J 1990; 269: 1-11.
20. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G et al. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62: 427-433.
21. Paré G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY et al. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: A genome-wide evaluation of 14,618 participants in the Women's genome health study. PLoS Genet 2008; 4(12): 1-8. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=19096518.
22. Martín-Gallan P, Carrascosa A, Gussinyé M, Domínguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34 (12): 1563-1574.
23. Chiarelli F, Martino M, Mezzetti A, Catino M, Morgese G, Cuc-curullo F et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 1999; 134 (4): 486-491.
24. Vander Jagt D, Harrison J, Ratliff D, Hunsaker L, Vander Jagt DL. Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem 2001; 34(4): 265-270.
25. Shamir R, Kassis H, Kaplan M, Naveh T, Shehadeh N. Glycemic control in adolescents with type 1 diabetes mellitus improves lipid se rum levels and oxidative stress. Pediatr Diabetes 2008; 9 (2): 104-109.
26. Ladeia AM, Adan L, Couto-Silva AC, Hiltner A, Gumiráes AC. Lipid profile correlates with glycemic control in young patients with type 1 diabetes mellitus. Prev Cardiol Spring 2002; 9 (2): 82-88.
27. Martinez MT, Ramos O, Carretero N, Cavillán M, Gutierrez-López MD, Cuesta P et al. Lipoprotein (a) and other risk factors in children with insulin-dependent diabetes mellitus and children without diabetes. Diabete Metab 1994; 20 (6): 522-525.
28. Petitti DB, Imperatore G, Palla SL, Daniels SR, Dolan LM, Kershnar AK et al. Serum lipids and glucose control: the search for diabetes in youth study. Arch Pediatr Adolesc Med 2007; 161 (2): 159-165.
29. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hans-sen KF. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46 (6): 661-665.
30. Magalhǎes PM, Appell HJ, Duarte JA. Involvement of advanced glycation end products in the pathogenesis of diabetic complications: the protective role of regular physical activity. Eur Rev Aging Phys Act 2008; 5: 17-29.
31. Sampathkumar R, Balasubramanyam M, Rema M, Premanand C, Mohan V. A novel advanced glycation index and its association with diabetes and microangiopathy. Metabolism 2005; 54 (8): 1002-1007.
32. Busch M, Franke S, Stein G, Wolf G. Is the serum concentration of pentosidine a predictor of cardiovascular events in patients 1,0 with type 2 diabetes and kidney disease? Dtsch Med Wschr 2007; 132(36): 1810-1814.
33. Hatfield J. Advanced glycation end-products (AGEs) in hyperglycemic patients. J Young Invest 2008; 19(3). Available at http://www.jyi.org/research/re.php?id=575.
34. Chiarelli F, Catino M, Tumini S, Cipollone F, Mezzetti A Vanelli M et al. Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Pediatr Nephrol 2000; 14 (8-9): 841-846.
35. Kalousová M, Škrha J, Zima T. Advanced Glycation End-Products and Advanced Oxidation Protein Products in Patients with Diabetes Mellitus. Physiol Res 2002; 51 (6): 597-604.
36. Buongiorno AM, Morelli S, Sagratella E, Castaldo P, Di Virgilio A, Marocca E et al. Levels of advanced glycosylation end-products (AGE) in sera of pregnant diabetic women: comparison between type 1 and type 2 and gestational diabetes mellitus. Ann 1st Super Sanita 1997; 33: 375-378.
37. Nicoloff G, Baydanoff S, Petrova Ch, Christova P. Antibodies to advanced glycation end products in children with diabetes mellitus. Vascul Pharmacol 2002; 39 (1-2): 39-45.
38. Shimoike T, Inuguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000; 49 (8): 1030-1035.
39. Kalousová M, Zima T, Tesař V, Skrha J, Štipek S. štanoveni produktů pokročilé glykace a oxidace. Klin Biochem Metab (Czech) 2002; 10(1): 11-16.
40. Mylona-Karayanni C, Gourgiotis D, Bossios A, Kamper EF. Oxidative stress and adhesion molecules in children with type 1 diabetes mellitus: a possible link. Pediatr Diabetes 2006; 7 (1): 51-59.
41. Hsu WT, Tsai LY, Lin SK, Hsiao JK, Chen BH. Effects of diabetes duration and glycemic control on free radicals in children with type 1 diabetes mellitus. Ann Clin Lab Sci 2006; 36 (2): 174-178.